The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Xinlin Liu; Junwen Deng; Renshuai Zhang; Jiyao Xing; Yudong Wu; Wujun Chen; Bing Liang; Dongming Xing; Jiazhen Xu; Miao Zhang

doi:10.3389/fimmu.2023.1335252

The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy

Front Immunol. 2023 Dec 11:14:1335252. doi: 10.3389/fimmu.2023.1335252. eCollection 2023.

Authors

Xinlin Liu^{1

2}, Junwen Deng^{1

2}, Renshuai Zhang^{1

2}, Jiyao Xing^{1

2}, Yudong Wu^{1

2}, Wujun Chen^{1

2}, Bing Liang^{1

2}, Dongming Xing^{1

2

3}, Jiazhen Xu^{1

2}, Miao Zhang^{1

2}

Affiliations

¹ The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.
² Qingdao Cancer Institute, Qingdao, China.
³ School of Life Sciences, Tsinghua University, Beijing, China.

Abstract

Despite the emergence of molecular targeted therapy and immune checkpoint inhibitors as standard first-line treatments for non-small cell lung cancer (NSCLC), their efficacy in some patients is limited by intrinsic and acquired resistance. Antibody-drug conjugates (ADCs), a revolutionary class of antitumor drugs, have displayed promising clinical outcomes in cancer treatment. In 2022, trastuzumab deruxtecan (Enhertu) was approved for treating HER2-mutated NSCLC, thereby underscoring the clinical value of ADCs in NSCLC treatment strategies. An increasing number of ADCs, focusing on NSCLC, are undergoing clinical trials, potentially positioning them as future treatment options. In this review, we encapsulate recent advancements in the clinical research of novel ADCs for treating NSCLC. Subsequently, we discuss the mechanisms of action, clinical efficacy, and associated limitations of these ADCs.

Keywords: NSCLC; antibody-drug conjugate; clinical outcome; mechanisms of action; targeted therapy.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Immune Checkpoint Inhibitors
Immunoconjugates* / therapeutic use
Lung Neoplasms* / drug therapy
Molecular Targeted Therapy

Substances

Immunoconjugates
Immune Checkpoint Inhibitors

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This study was supported by the Natural Science Foundation of Shandong Province Grants ZR2022QH201 (XL) and the National Natural Science Foundation of China Grants 32300788 (XL).